A second phase of revisions is reflected in the newly posted standards. These developments and new information about heparin were discussed by scientists and regulators at the third International Heparin Workshop held at USP headquarters in Rockville, Maryland, July 27.
"While financially-motivated adulteration of medicines is a distressingly persistent problem," noted Roger L. Williams, M.D., USP's chief executive officer, "I'm pleased at the progress we've made in helping to ensure that such tragic events are minimized. Stronger methods for detecting a range of potential contaminants have been thoroughly assessed and incorporated into the new test methods, and the new physical reference standards are specific to these methods. Manufacturers—and in consequence, physicians and their patients—can feel more confident of the purity and integrity of their heparin products."
The Workshop, co-sponsored by USP, the British National Institute of Biological Standards and Control (NIBSC), and the European Directorate for the Quality of Medicines (EDQM), reflected the global nature of both the problem of adulteration and the resources cooperating to combat it, with attendees from more than 17 countries.
The updated written standards are the Heparin Sodium Stage 2 Monograph and the Heparin Sodium Injection Stage 2 Monograph; new reference standards are Heparin Sodium for Assays, Oversulfated Chondroitin Sulfate, and Dermatan Sulfate. These and other related standards and information are available at http://www.usp.org/hottopics/heparin.html.
The new Heparin standards will become official on October 1, 2009.
By US Pharmacopeia